Nanocopoeia is a drug-formulation company with a proprietary technology for producing nanoparticles. We offer our pharmaceutical partners improvements in compound solubility and bioavailability and new capabilities for site-specific delivery of therapeutic agents.

The Opportunity
Pharmaceutical companies face significant development and formulation challenges along the path to commercializing therapeutic compounds—including solubility, bioavailability, and delivery. For example, it is estimated that 40-50% of the potentially useful drug compounds emerging from the discovery process are insoluble in water. At the end of a commercial compound's patent life, drug companies develop new formulations of existing compounds to extend the market life of branded drugs. Nanoformulation (formulating compounds using nanotechnology) addresses each of these challenges.

Nanoformulation works by dramatically increasing surface area, making substances more soluble. This makes continued development of previously insoluble drug candidates possible, substantially improving return on R&D investment. Nanoformulation can also improve performance of drugs by speeding onset of action, enabling alternative delivery routes such as delivery across the skin or mucous membranes, or even targeting specific tissues.

Unique Technology
Nanocopoeia's proprietary ElectroNanospray™ formulation technology produces precise, ultra-pure nanoparticles. Particle sizes can be designed from 2-200 nm. The device is capable of applying a coating to the particles in a single-process step, producing a drug-loaded core. Competitive processes to produce nanoparticles using wet milling and supercritical fluid are inherently limited in their ability to produce consistently pure particles within a specified size range and distribution or of producing coated particles.

The Business
Nanocopoeia works in collaboration with pharmaceutical, biotech, and medical device partners to solve key formulation and delivery challenges. Nanocopoeia provides enabling technology to corporate partners in support of research collaborations. Revenue is generated based on research services, milestones and licensing, production of clinical trial material and royalties generated from formulations and coated devices that reach the commercial market.